A leading prostate cancer researcher was sued by a biotechnology company for making false statements about a biomarker to detect prostate cancer, according to a surprising story in Pittsburgh. Tribune-Review yesterday
article indicates that in 01, Robert Getzenberg and the University of Pittsburgh has claimed to find a prostate cancer biomarker called EPCA-2 that its patented University . This led to the formation of a company, Onconome Inc. to develop and market. Getzberg became a consultant to the company. But now Onconome, based in Redmond, Washington, Getzenberg continues in federal court for the presentation of scientific results over 6 years "have been and are imaginary," the trial would have said. Getzenberg is now at Johns Hopkins University in Baltimore, Maryland.
0 Komentar